The Wilms' tumour gene 1 (WT1) protein is highly expressed in most leukaemias. Co-expression of WT1 and the fusion protein AML1-ETO in mice rapidly induces acute myeloid leukaemia (AML). Mechanisms behind expression of WT1, as well as consequences thereof, are still unclear. Here, we report that the fusion protein BCR/ABL1 increases expression of WT1 mRNA and protein via the phosphatidylinositol-3 kinase (PI3K)-Akt pathway. Inhibition of BCR/ABL1 or PI3K activity strongly suppressed transcription from WT1 promoter/enhancer reporters. Forced expression of BCR/ABL1 in normal human progenitor CD34
Introduction
The Wilms' tumour gene 1 (WT1) encodes a transcription factor of the zinc-finger family which is critical for the development of gonads, kidneys, liver, spleen, heart and mesenchymal structures (reviewed in Lee and Haber (2001) ; Scharnhorst et al. (2001) 1,2 ). Somatic homozygous mutation or loss of WT1 predisposes for the paediatric kidney cancer Wilms' tumour. 3, 4 In normal haematopoietic cells, WT1 is highly expressed in a subset of progenitors. [5] [6] [7] [8] [9] [10] Analysis of lineage potential of haematopoietic progenitors from knockout mice demonstrates that WT1 is not critical for haematopoiesis, at least not in mice, 11 although murine progenitors lacking WT1 are less competitive during haematopoietic reconstitution in vivo, 12 suggesting positive effects of WT1 on proliferation and/or survival of haematopoietic cells.
Several observations support the notion of WT1 as a potential oncogene in the development of human leukaemia. WT1 is highly expressed in most leukaemias [13] [14] [15] [16] and expression is further increased upon relapse of the disease. 17 Upon induced differentiation of leukaemia cell lines, WT1 is rapidly downregulated 18, 19 and forced expression of WT1 in some leukaemia cell lines confers resistance to induction of differentiation. [20] [21] [22] Recently, it was reported that co-expression of WT1 and the fusion protein AML1-ETO in transgenic mice rapidly induces acute myeloid leukaemia (AML), 23 further emphasizing the oncogenic function of WT1.
Thus, a large amount of data indicate the importance of WT1 in haematopoiesis and leukaemogenesis, but neither the molecular mechanisms by which WT1 exerts its function in leukaemia cells, nor the mechanisms behind the high expression of WT1 in leukaemic cells, are well characterized. Recently, it was reported that inhibition of the tyrosine kinase activity of BCR/ABL1 in chronic myeloid leukaemia (CML) cells reduces the level of WT1 mRNA. 24 The BCR/ABL1 fusion gene is critical for the pathogenesis of CML and most, if not all, pathogenetic signals from BCR/ABL1 are dependent on the tyrosine kinase activity of BCR/ABL1 (reviewed in Ren (2005) 25 ). The aim of this work was to investigate signalling pathways from BCR/ABL1 influencing the expression of the WT1 gene and consequences thereof in CML cells. We present evidence that BCR/ABL1 signalling increases expression of the WT1 gene and protein via the phosphatidylinositol-3 kinase (PI3K)-Akt pathway. We also show that forced expression of WT1 in BCR/ABL1-positive CML cells confers resistance to apoptosis induced by inhibition of BCR/ABL1 signalling.
Materials and methods

Cell lines
The CML cell lines K562, JK-1, KU-812, LAMA-84 and MEG-01 (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) were maintained in RPMI1640 supplemented with 10-20% fetal calf serum (FCS) and grown in a 5% CO 2 atmosphere at 37 1C.
Reagents
To inhibit different signalling pathways, the cells were treated with imatinib mesylate (imatinib) (kindly provided by Dr E Buchdunger, Novartis, Basel, Switzerland), LY294002 (Calbiochem, Merck Biosiences, Merck KgaA, Darmstadt, Germany), 1L-6-hydroxymethyl-chiro-inositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate] (Alexis Biochemicals, San Diego, CA, USA) and Rapamycin (Cell signalling Technology, Beverly, MA, USA). When investigating the WT1 mRNA stability, cells were treated with actinomycin D (Sigma, St Louis, MO, USA). Etoposide (Sigma) and As 2 O 3 (Sigma) were used to induce apoptosis. Concentrations used are indicated in figure legends.
Isolation of CD34
þ cells from umbilical cord blood
Umbilical cord blood was, after ethical approval and informed consent, collected from mothers giving birth to normal, full-term infants. CD34 þ cells were enriched as described. 26 CD34 þ cell purity was always more than 90% as determined by flow cytometric analysis.
Retroviral constructs and transduction of CD34
þ cells
The MSCV-BCR/ABL1-IRES-GFP vector was kindly provided by Dr C Eaves (Terry Fox Laboratory, Vancouver, Canada) and it contains the human cDNA for p210 BCR/ABL1, an internal ribosomal entry site (IRES) and green fluorescent protein (GFP). Retroviral vectors encoding different forms of WT1 were as described earlier. 26 Retroviral producer cell lines expressing the feline endogenous virus envelope protein RD114 27 were obtained and virus containing medium was harvested as previously described, 26 although MSCV-BCR/ABL1-IRES-GFP was only transiently transfected to packaging cells. CD34 þ cells were transduced and subjected to cell sorting of GFP þ cells as described. 26 
RNA isolation and reverse transcription for real-time PCR
To analyse the expression of WT1 and GATA-1 mRNA, total RNA was isolated using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen, Gmbh, Hilden, Germany). Reverse transcription (RT) was carried out using TaqMan Reverse Transcriptase reagents (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. From BCR/ABL1-transduced CD34 þ progenitor cells, 500 GFP þ cells were sorted directly into PCR tubes containing cell lysis buffer, after which the RT reaction was performed using a Sensiscript RT kit (Qiagen) as described elsewhere. 28 
Real-time PCR
Real-time PCR was carried out using TaqMan probe-based chemistry (Applied Biosystems). Primers/probes for WT1 (Hs00240913_m1), GATA-1 (Hs00231112_m1) and the endogenous controls 18S (Hs99999901_s1) and b2-microglobulin (4326319E) were purchased as Assay-on-Demand (Applied Biosystems). The amplification reactions were all performed in triplicates in an ABI Prism 7000 Sequence Detection System according to the manufacturer's instructions with the following exception: when analysing gene expression from only 500 sorted GFP þ progenitor cells, 5 ml of the cDNA was used in each 25 ml PCR reaction, as described elsewhere. 28 Data was collected and analysed with Sequence Detector v.1.1 software (Applied Biosystems). Relative quantitative data based on the DDC T method. 29 was calculated. Normalization:
Western blot analysis
Protein lysates were prepared and western blotting was performed as previously described, 30 
Proliferation assays
Cell number was counted in a Bü rker chamber and viability was determined by trypan blue exclusion. CellTiter 96Aqueous One Solution Cell Proliferation Assay (Promega) was used according to the manufacturer's instructions, giving a determination of metabolic activity.
Analysis of viability and apoptosis by flow cytometry
The frequency of apoptotic cells was determined by co-staining cells with annexin V-PE (BD Biosciences-Pharmingen, San Jose, CA, USA) and DAPI (4 0 ,6-diamidino-2-phenylindole) (Sigma). DAPI was added prior to fluorescence-activated cell sorting (FACS) analysis to discriminate and quantify dead (DAPI permeable) from viable cells (DAPI impermeable). The percentage of cells within the populations positive for DAPI and positive for annexin V was determined by analysis in a FACS Aria.
Results
Inhibition of BCR/ABL1 in CML cell lines downregulates WT1 expression
A recent report showed that WT1 mRNA levels decreased after treatment of CML cells with the ABL1 tyrosine kinase inhibitor imatinib, 24 suggesting that expression of WT1 is dependent on the tyrosine kinase activity of BCR/ABL1. We therefore set out to investigate the signalling pathways by which BCR/ABL1 induces WT1 mRNA expression. Five BCR/ABL1-positive CML cell lines were treated with 1 mM imatinib mesylate, a potent and specific inhibitor of the tyrosine kinase activity of BCR/ABL1. After 6 h, RNA was isolated and WT1 expression was analysed by realtime RT-PCR. WT1 mRNA levels were decreased in all five cell lines after imatinib treatment: K562: 27% of control; JK-1: 33% of control; KU-812: 41% of control; LAMA-84: 54% of control and MEG-01: 37% of control; confirming and extending previous data.
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BCR/ABL1 increases WT1 expression via the PI3K-Akt signalling pathway
Signalling from BCR/ABL1 is dependent on its tyrosine kinase activity and well characterized downstream signalling pathways include the PI3K-Akt pathway, MAP kinase pathway, and the JAK-STAT pathway (reviewed in Ren (2005) 25 ). To characterize the signalling pathway mediating the BCR/ABL1 effect on WT1 expression, K562 cells were treated for 6 h with imatinib, PI3K inhibitor (LY294002), Akt inhibitor (1L-6-hydroxymethyl-chiroinositol 2-[(R)-2-O-methyl-3-O-octadecylcarbonate]) or with rapamycin, which inhibits mTOR. Treatment of the cells with imatinib reduced the levels of WT1 mRNA, consistent with results described above ( Figure 1a ). Inhibition of PI3K or Akt also resulted in a strong decrease of WT1 mRNA (Figure 1a ), making us conclude that WT1 mRNA expression is highly dependent on PI3K and Akt signalling. The lack of effect of rapamycin on WT1 mRNA indicate that mTOR, a substrate downstream of Akt, is not involved in this signalling. To assure that rapamycin indeed inhibited mTOR activity, the phosphorylation of p70S6K (a substrate phosphorylated by mTOR) was analysed. As expected, rapamycin strongly inhibited phosphorylation of p70S6K ( Figure 1b) . To address the question whether WT1 expression was dependent also on JAK-STAT signalling, STAT5 phosphorylation was evaluated after addition of the inhibitors. As shown in Figure 1c , inhibition of BCR/ABL1 with imatinib completely blocked STAT5 phosphorylation, as expected. However, STAT5 phosphorylation was not at all affected by the Akt inhibitor and was rather increased by the PI3K inhibitor, conditions that strongly reduced WT1 mRNA levels ( Figure 1a ). These results indicate that BCR/ABL1-induced upregulation of WT1 mRNA and protein is mediated via the PI3K-Akt and not the JAK-STAT pathway.
Inhibition of BCR/ABL1 or PI3K activity decreases WT1 protein levels
To investigate whether reduction of WT1 mRNA also results in decreased levels of WT1 protein, K562 cells were treated with imatinib or with the PI3K inhibitor LY294002, giving robust reduction of WT1 mRNA (Figure 1a ), after which WT1 protein was analysed by western blot. As shown in Figure 2 , treatment with imatinib or LY294002 also resulted in decreased levels of WT1 protein.
BCR/ABL1 or PI3K signalling does not affect WT1 mRNA stability
To address the question whether BCR/ABL1-mediated effects of WT1 mRNA expression was due to increased WT1 mRNA stability, K562 cells were treated for 45 min with or without the PI3K inhibitor LY294002, after which 5 mg ml À1 actinomycin D was added to block all de novo mRNA synthesis. Samples taken 1, 2, 3, 4 and 5 h after addition of actinomycin D were subjected to real-time RT-PCR analysis of WT1 mRNA. As shown in Figure 3 , WT1 mRNA stability was not significantly affected by PI3K inhibition. Similar results were obtained with imatinib, blocking the tyrosine kinase activity of BCR/ABL1 (data not shown). We conclude that neither BCR/ABL1, nor PI3K signalling, does affect the half-life of WT1 mRNA, suggesting that the observed effects on WT1 mRNA is rather dependent on transcriptional regulation.
PI3K increases WT1 mRNA levels via transcriptional activation
To obtain support for transcriptional effects on the WT1 gene, a WT1 promoter construct (pCB.7PH), as well as WT1 promoter constructs containing an intron 3 enhancer (pCB.7e258), a 3' enhancer (pCB.7e250) or both enhancers (pCB.7e250e258), were transfected into K562 cells. The enhancer-containing reporters have previously been shown to be transcriptionally active in K562 cells, showing haematopoietic specific activity and functional GATA-1 sites. 31, 32 As expected, the WT1 promoter constructs containing either one or both of the enhancers were highly active in control cells. Inhibition of PI3K dramatically decreased the reporter activity of all constructs containing enhancer regions (Figure 4) . A control promoter (pGL3promoter, Promega) coupled to luciferase was downmodulated approximately 30% after identical treatment with PI3K inhibitor, indicating some unspecific downmodulation of reporter activity. Therefore, the observed downmodulation of WT1 promoter only (28%) (Figure 4 bottom) might be due to unspecific downregulation of reporter in treated cells. We conclude that activity of the intron 3 enhancer and in particular the 3' enhancer is strongly and specifically downmodulated after PI3K inhibition. Comparable inhibition of enhancer activity, although to a somewhat lesser extent, was obtained after inhibition of BCR/ABL1 with imatinib (data not shown). 
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From present data the transacting factor responsible for regulation of WT1 enhancers cannot be identified, but given the presence of functional GATA-1 sites in the enhancers, 31, 32 GATA-1 could hypothetically be involved. We conclude that inhibition of PI3K or BCR/ABL1 strongly decreases the transcriptional activity of WT1 enhancers, indicating that BCR/ ABL1, via PI3K, increases transcription of the WT1 gene.
Expression of BCR/ABL1 in progenitor cells induces WT1 mRNA and protein levels
To obtain further evidence for a regulatory relationship between BCR/ABL1, WT1 and possibly GATA-1 in haematopoietic progenitors, CD34
þ cells from cord blood were retrovirally transduced with a vector encoding BCR/ABL1 and GFP. Expression of BCR/ABL1 in CD34
þ human progenitor cells recreates many phenotypic features of primary CML cells. 33, 34 GFP þ cells were isolated by cell sorting 24 and 48 h posttransduction, after which RNA was isolated and subjected to real-time RT-PCR analysis. The transduction efficiencies obtained were around 80% for the control vector and 15% for the BCR/ABL1 vector. As shown in Figure 5a , expression of BCR/ ABL1 indeed resulted in enhanced levels (approximately 12-fold) of WT1 mRNA 24 h post-transduction, and levels remained increased (approximately threefold) after 48 h. Interestingly, BCR/ABL1 expression also resulted in approximately fourfold increase of GATA-1 mRNA after 24 h (Figure 5a ). The increase in GATA-1 mRNA levels were further increased 48 h posttransduction (Figure 5a ). These data do not support the hypothesis that transcriptional upregulation of GATA-1 levels is responsible for increase of WT1 mRNA, but rather that increased amount of GATA-1 is part of the erythroid phenotype induced by BCR/ABL1. 33, 34 Finally, upon analysis of protein levels in BCR/ABL1-transduced progenitors (200 000 cells), we could demonstrate that the WT1 protein was increased three-to fourfold, showing regulation of WT1 also at the protein level in progenitor cells (Figure 5b ). Due to limitations in the number of CD34 þ cells, extract from only 200 000 cells was analysed, which should be compared to extracts from 500 000 K562 (positive control) and U937 cells (negative control).
Retroviral expression of WT1 in K562 protects against imatinib-induced apoptosis
Results described above demonstrate that BCR/ABL1 signalling induces increased levels of WT1 mRNA and protein. The functional role of WT1 in leukaemogenesis is not clear, but in some experimental models an anti-apoptotic effect of WT1 has been reported. [35] [36] [37] We therefore hypothesized that BCR/ABL1-induced WT1 contributes to increased viability in CML cells. To investigate this hypothesis, we overexpressed WT1 in K562 cells after which sensitivity for imatinib was analysed. WT1 is a transcription factor with DNA-binding zinc fingers. Alternative splice variants of WT1 include or exclude 17 amino acids close to the zinc fingers (717AA) and a three amino acid (lysinethreonine-serine) insert between zinc-fingers 3 and 4 (7KTS (amino acids)).
1,2
We stably expressed two splice forms of WT1 (with and without KTS amino acids), as well as a zinc finger-deleted WT1 unable to bind DNA (WT1delZ), using retroviral transduction into K562 cells. GFP þ cells were isolated by cell sorting and the GFP þ cell populations were expanded 48 h post-transduction. The transduction efficiencies obtained were between 48 and 67% for all of the vectors. First, to confirm overexpression of WT1 in transduced cells, protein levels were investigated after 48 h of imatinib treatment. As expected, endogenous WT1 protein was decreased by imatinib in MIG-transduced (vector with GFP only) control cells, while WT1-transduced cells retained expression of WT1 protein (Figure 6 ), consistent with the notion of specific effects of imatinib on transcription from the endogenous WT1 gene.
Next, the GFP þ cell populations were cultured with or without 3 mM imatinib, during which proliferation and cell death were analysed after 24, 48, 72 and 96 h. As shown in Figure 7 , overexpression of WT1 did neither affect the proliferation 
, zinc finger-deleted WT1 (WT1(delZ)) or with MIG as control, were treated with 3 mM imatinib. After 48 h of treatment, WT1 protein levels were examined by western blot. Arrows indicate the different WT1 isoforms. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control of equal loading. Molecular weight markers to the left. (Figure 7a ) nor the viability (Figure 7b ) in cells cultured in the absence of imatinib. However, in cells treated with 3 mM imatinib, a strong decrease in proliferation was seen in all samples except in WT1( þ 17AA/ þ KTS)-transduced cells, which continued to proliferate, although at a slower rate as compared to untreated cells (Figure 7a ). Upon analysis of viability of imatinib-treated cells, forced expression of either WT1( þ 17AA/ þ KTS) or WT1( þ 17AA/ÀKTS) isoforms, but not the zinc-finger deleted WT1(delZ), conferred a preserved viability, as compared to MIG-transduced control cells (Figure 7b ). These results indicate that both investigated WT1 isoforms protect from imatinib-induced cell death, while the WT1( þ 17AA/ þ KTS) isoform also entails some proliferation in spite of imatinib treatment. Coherent results were obtained upon analysis of imatinib-treated cells using the cell titre assay which measures metabolic activity in the cells; compared to MIG-and WT1(delZ)-transduced cells, the WT1( þ 17AA/ÀKTS), and in particular WT1( þ 17AA/ þ KTS)-transduced cells, showed higher absorbance values as a sign of higher metabolic activity (Figure 7c ). To further characterize the cell death, cells were stained with annexin V or with DAPI after imatinib treatment. Annexin V is a marker for early apoptosis and DAPI is a marker for dying cells. As shown in Figure 7d and e, both WT1( þ 17AA/ þ KTS)-and WT1( þ 17AA/ÀKTS)-transduced cells showed decreased number of annexin V-positive, as well as DAPIpositive cells, as compared to control MIG and WT1(delZ)-transduced cells, after treatment with imatinib.
WT1 mediates resistance to imatinib
The above-described results were obtained with 3 mM imatinib. At a lower dose of imatinib, 1 mM, WT1 mediated similar effects on proliferation and viability (data not shown). We conclude that sustained expression of WT1 protects CML cells from imatinib-induced apoptosis.
Forced expression of WT1 does not provide protection against arsenic or etoposide-induced apoptosis
Given the protection against imatinib, we now asked whether forced expression of WT1 might decrease the sensitivity of the cells to other apoptosis-inducing agents. To address this issue, transduced GFP þ cells were treated with etoposide or with arsenic trioxide (As 2 O 3 ) during 24 h, after which the degree of apoptosis and cell death was analysed by annexin V and DAPI staining. As 2 O 3 is an arsenic derivative with potent cytostatic and cytotoxic effects used in the treatment of acute promyelocytic leukaemia and is of potential use also in CML (reviewed in Miller (2002) 38 ). The exact functional mechanism for As 2 O 3 on leukaemic cells is still unclear, but may involve downregulation of anti-apoptotic bcl-2 family members, increased expression of proapoptotic bax or altered subnuclear distribution of PML (reviewed in Miller (2002) 38 ). Interestingly, treatment of leukaemia cell lines with As 2 O 3 induces downregulation of WT1 expression. 39 However, when treating transfected K562 cells with three different concentrations of As 2 O 3 (5, 10 and 25 mM), clearly inducing cell death and apoptosis in control cells, neither of the WT1 forms showed any protective effects (Figure 8a ). 
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Etoposide is an antitumour agent, which through complex formation with topoisomerase II and DNA enhances cleavage of single-and double-strand breaks in DNA and prevents relegation. Upon treatment of leukaemic cells with etoposide, apoptosis is detected, possibly involving the bcl-2 family members bcl-2, bcl-X L and bax. 40, 41 Upon treatment of transfected K562 cells with 10, 25 or 50 mM etoposide, only the highest concentration (50 mM) resulted in robust apoptosis, as determined by annexin V and DAPI positivity (Figure 8b ). At this concentration WT1( þ 17AA/ þ KTS) enhanced apoptosis, rather than provided an anti-apoptotic effect (Figure 8b ). WT1( þ 17AA/ÀKTS) and WT1(delZ) conferred no, or only weak, protection against etoposide-induced apoptosis (Figure 8b) . We conclude that while WT1 clearly protects against imatinib, forced expression of WT1 does not protect against As 2 O 3 -induced cell death and not, or only weakly, against apoptosis induced by etoposide.
Discussion
The WT1 is highly expressed in leukaemia cells. [13] [14] [15] [16] Here we show that expression of WT1 is positively regulated by BCR/ ABL1. This conclusion is based on the finding that imatinib in several BCR/ABL1-expressing cell lines reduced the amount of WT1 mRNA and protein, while forced expression of BCR/ABL1 in CD34 þ progenitors increased the levels of WT1 mRNA and protein.
The oncogenic property of the constitutively active tyrosine kinase BCR/ABL1 is evident when overexpressed in human CD34 þ progenitor cells, causing increased proliferation and survival. 33, 34 Moreover, BCR/ABL1-transduced CD34 þ cells transplanted to mice results in expansion of myeloid, erythroid and megakaryocytic cells with progression into a myeloproliferative disease. 42 Signalling pathways activated in BCR/ABL1-positive cells have been characterized (reviewed in Ren (2005) 25 ). The main signalling pathways involved downstream of BCR/ABL1 are the MAP kinase, JAK-STAT and PI3K-Akt pathway. BCR/ABL1-positive cells seem to require PI3K activity for proliferation, 43 and active Akt, which lies downstream of PI3K in a phosphorylation cascade, has been associated with anti-apoptotic signalling (reviewed in Stokoe (2005) 44 ). We demonstrate that modulation of WT1 expression downstream of BCR/ABL1 is mediated via the PI3K-pathway, since addition of PI3K inhibitor mediated a strong repression of the WT1 mRNA levels as compared to untreated cells. Akt is a main target of PI3K (reviewed in Stokoe (2005) 44 ). Consistently, WT1 mRNA levels were robustly reduced also by inhibition of the kinase activity of Akt. We can therefore conclude that BCR/ ABL1-mediated regulation of WT1 mRNA levels involves PI3K and Akt. Not only BCR/ABL1, but also other receptor tyrosine kinases, many of which are involved in leukaemogenesis, signal for activation of PI3K and Akt (reviewed in Stokoe (2005) ; Blume-Jensen and Hunter (2001) 44, 45 ). It remains to be investigated whether constitutive signalling from any of these also can increase the expression levels of WT1, but it is interesting that the HER2/neu tyrosine kinase oncogene in breast cancer cells can increase the expression of WT1 via a mechanism involving Akt. 46 Thus, tyrosine kinase-driven expression of WT1 may not be restricted to CML cells.
Another major signalling pathway from BCR/ABL1 involves JAK kinases leading to phosphorylated STAT proteins, in particular STAT5, affecting gene transcription. 47 To analyse the involvement of JAK-STAT signalling in WT1 regulation, we compared the effects of inhibition of BCR/ABL1, PI3K or Akt on both the levels of WT1 mRNA and on the phosphorylation of STAT5. While the BCR/ABL1 inhibitor imatinib, as expected, completely blocked STAT5 phosphorylation and reduced WT1 mRNA, inhibition of PI3K or Akt was without any effect on STAT5 phosphorylation, whereas WT1 mRNA levels nevertheless were efficiently reduced. We can therefore conclude that BCR/ABL1-induced expression of WT1 is not dependent on JAK-STAT signalling, at least not via STAT5 phosphorylation. It should be noted that we from present data cannot exclude a possible contribution from MAP kinase signalling in the regulation of WT1.
Our finding that the stability of WT1 mRNA was not affected by BCR/ABL1 kinase signalling, as demonstrated by unchanged half-life of the mRNA after treatment of the cells with imatinib or with a PI3K inhibitor, strongly indicates that the observed effects on WT1 mRNA is dependent on transcriptional regulation of the WT1 gene. The WT1 promoter is GC rich but lacks TATA and CAAT sequences and is functional in most cell lines tested, 48 suggesting that tissue specificity of WT1 expression is given by other cis-regulatory elements. Indeed, haematopoietic-specific enhancer elements have been identified both at the 3' end and in the third intron of the WT1 gene. 31, 32 Our finding that the transcriptional activity of these haematopoietic-specific enhancers are strongly repressed in cells treated with imatinib or with PI3K inhibitor gives firm support for the notion that BCR/ABL1-PI3K signalling confers increased WT1 mRNA via transcriptional activation of the WT1 gene. The identity of the transcription factor(s) involved in the PI3K-mediated transactivation of the WT1 gene is presently unknown, but both the 3' enhancer and the intron 3 enhancer are transactivated by GATA-1. 31, 32 Interestingly, BCR/ABL1-mediated transactivation of the Hsp70 gene is dependent on a functional GATA-1 site, 49 suggesting that BCR/ABL1 might activate GATA-1. Moreover, PI3K signalling downstream of the erythropoietin receptor stimulates phosphorylation and activation of GATA-1, indicating posttranslational activation of GATA-1 involving PI3K-Akt. 50 Thus, post-translational activation of GATA-1 is a potential mechanism of the PI3K-Akt induced transcriptional activation of the WT1 gene. Given that BCR/ABL1 can direct human progenitor cells into erythroid differentiation and erythropoiesis, 33 ,34 the present finding that expression of BCR/ABL1 with time also strongly increases the mRNA levels of the erythroid-associated transcription factor GATA-1 mRNA is interesting. Intriguingly, WT1 was recently shown to act as a transcriptional activator of the erythropoietin gene, 51 raising the hypothesis that both GATA-1 and WT1 play roles in BCR/ABL1-induced erythroid phenotype. The strong rise in WT1 mRNA levels preceding that of GATA1 does not support, however, that transcriptional upregulation of GATA1 mediates BCR/ABL1-induced transcription of the WT1 gene. Posttranslational activation of GATA1 (50) by BCR/ABL1 remains though a hypothetical mechanism by which GATA1 could transactivate WT1 and other erythroid associated genes.
What are the functional consequences of increased WT1 levels induced by BCR/ABL1? Increased levels of WT1 during development of CML into blast crisis 52 suggest that WT1 is involved in disease progression. The present investigation demonstrates that WT1 is an important mediator of oncogenic survival signals downstream of BCR/ABL1. This conclusion is based on the finding that forced expression of WT1( þ 17AA/ þ KTS), as well as of WT1( þ 17AA/ÀKTS), provided protection against the cytotoxic effect of the BCR/ABL1 tyrosine kinase inhibitor imatinib. Since the zinc finger-deleted WT1(delZ) showed no protection, the effect was dependent on DNA binding and therefore most likely involves gene regulation WT1 mediates resistance to imatinib E Svensson et al exerted by WT1. Overexpression of WT1 in some cell lines has resulted in increased endogenous bcl-2 protein levels. 53 Upon analysis of bcl-2 protein, we could not detect any differences between control cells and WT1-transduced cells (data not shown), indicating that increased levels of bcl-2 is not responsible for the anti-apoptotic effect of WT1. The absence of protection against treatment with As 2 O 3 or with etoposide in WT1-transduced cells are consistent with WT1 acting on specific pathways related to signalling downstream of BCR/ ABL1. In consistence with this notion, WT1 overexpression did not alter induction of apoptosis in K562 cells induced by cisplatin or adriamycin. 54 Very recently, it was reported that imatinib-induced killing of CML cells is mediated by upregulation of Bim and Bad. 55 It remains to be investigated whether WT1 affects other bcl-2 family members than bcl-2 in imatinibtreated CML cells. Interestingly, the WT1( þ 17AA/ þ KTS) form not only protected from cell death, but also supported proliferation during treatment with imatinib. The molecular mechanism underlying the enhanced proliferative effect of WT1( þ KTS) remains to be further examined.
The only weak effect in protection against etoposide is not fully consistent with a recent report that WT1 indeed potently inhibits apoptosis induced by etoposide in K562 cells. 37 The explanation for the somewhat different results in our and that report is unclear, but could be related to different K562 subclones used, or other differences between experimental setups. In the study of Ito et al., 37 monoclonal lines of K562 overexpressing WT1 were isolated by growth under selective conditions. This is in contrast to the present study, in which polyclonal cells sorted for GFP þ were used, without selective culture conditions.
In conclusion, we report that the BCR/ABL1 tyrosine kinase signals via PI3K and Akt for increased transcription of the WT1 gene, leading to raised levels of WT1 mRNA and protein.
Further, we demonstrate that sustained levels of WT1 protects against apoptosis induced by imatinib, suggesting that WT1 could be a potential target for therapy in CML.
